Skip to Main Content
For healthcare professionals

DAREON®-7: A Phase I, open-label, dose escalation and expansion trial to investigate safety and tolerability of DLL3/CD3 T-cell engager (obrixtamig) intravenous infusions in combination with standard of care (platinum and etoposide) in first-line treatment of patients with NECs (NCT06132113)1,2

DLL3/CD3 T-cell engager DAREON®-7, NCT06132113
DLL3/CD3 T-cell engager DAREON®-7, NCT06132113

AE, adverse events; CD3, cluster of differentiation 3; DLL3, delta-like canonical Notch ligand 3; DLT, dose-limiting toxicity; DoR, duration of response; epNEC, extrapulmonary neuroendocrine carcinoma; IHC, immunohistochemistry; LCNEC-L, large cell neuroendocrine carcinoma of the lung; MTD, maximum tolerated dose; NEC, neuroendocrine carcinoma; OR, objective response; RDE, recommend dose for expansion; RECIST, Response Evaluation Criteria In Solid Tumours; SoC, standard of care.

References

  1. ClinicalTrials.gov. NCT06132113. https://classic.clinicaltrials.gov/ct2/show/NCT06132113 (Accessed: August 2025).

  2. Capdevila J, et al. AACR 2024. Poster CT090.